Peptide Changes: FDA Status, Safety and Dosing Updates

Corrected Oct 7, 2026: pancreatitis history, gastroparesis and pregnancy are US Adlyxin label cautions, not contraindications, per the FDA label.

Before: History of pancreatitis or active pancreatic disease; Severe gastrointestinal disease including gastroparesis; Pregnancy and breastfeeding (no adequate human data; animal studies showed adverse fetal effects) After: History of pancreatitis, gastroparesis, and pregnancy or breastfeeding: each marked as a US Adlyxin label caution or limitation of use, not a contraindication

Peptides: Lixisenatide

Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) · Saved copy

Corrected Oct 7, 2026: the US Adlyxin label does not recommend lixisenatide in end-stage renal disease; it is not a contraindication, per the FDA label.

Before: The drug is contraindicated at eGFR below 15. After: The US label does not recommend it in end-stage renal disease (eGFR below 15), where there is no therapeutic experience.

Peptides: Lixisenatide

Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) · Saved copy

Corrected Oct 7, 2026: end-stage renal disease now reads as a label warning on the contraindication list, not a contraindication, per the US Adlyxin label.

Before: End-stage renal disease (eGFR <15 mL/min) or dialysis: limited data and renal elimination pathway After: End-stage renal disease (eGFR <15 mL/min) or dialysis: not recommended on the US Adlyxin label (no therapeutic experience); a label warning, not a contraindication

Peptides: Lixisenatide

Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) · Saved copy

Corrected Oct 7, 2026: severe renal impairment is a Byetta label warning, not a contraindication; drug-induced thrombocytopenia is now listed, per the label.

Before: Exenatide is renally eliminated and contraindicated when eGFR falls below 30 mL/min. After: The Byetta label does not recommend it with severe renal impairment (creatinine clearance below 30 mL/min) or end-stage renal disease. Drug-induced immune-mediated thrombocytopenia added.

Peptides: Exenatide (Byetta / Bydureon)

Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) · Saved copy

Corrected Oct 7, 2026: pregnancy and severe gastroparesis are Byetta label cautions, not contraindications, per the Byetta label.

Before: Pregnancy or breastfeeding: not studied; potential fetal harm based on animal data; Severe gastrointestinal disease (e.g., gastroparesis) After: Pregnancy or breastfeeding: a Byetta label caution, not a contraindication; Severe gastroparesis: not recommended per the Byetta label (a warning, not a contraindication)

Peptides: Exenatide (Byetta / Bydureon)

Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) · Saved copy

Corrected Oct 7, 2026: Byetta's label contraindicates exenatide after drug-induced thrombocytopenia; kidney and pancreatitis items are warnings, per the label.

Before: Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease; History of pancreatitis (both listed as contraindications) After: History of drug-induced immune-mediated thrombocytopenia from exenatide products (label contraindication); severe renal impairment or ESRD and pancreatitis marked as label warnings

Peptides: Exenatide (Byetta / Bydureon)

Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) · Saved copy

Corrected Oct 7, 2026: CagriSema's investigational status now cites an active Phase 3 trial (REDEFINE 3), not a withdrawn one, per ClinicalTrials.gov.

Before: Status source: ClinicalTrials.gov NCT07357766 only (a formulation trial withdrawn before enrolling) After: Status sources: ClinicalTrials.gov NCT05669755 (REDEFINE 3, Phase 3, active, not recruiting) and NCT07357766

Peptides: CagriSema

Source: ClinicalTrials.gov NCT05669755, REDEFINE 3 (CagriSema cardiovascular outcomes, Phase 3, active, not recruiting; last update posted Aug 31, 2026) · Saved copy

Corrected Oct 6, 2026: the dosing source and FAQ now give 2026, not 2025, as the year of Foundayo's first US approval, per the FDA record.

Peptides: Orforglipron

Source: Drugs@FDA record for Foundayo (orforglipron), NDA 220934 (openFDA) · Saved copy

Corrected Oct 6, 2026: the US Adlyxin label lists severe hypersensitivity as its only contraindication, not MTC or MEN 2, per the FDA label.

Before: The precautionary contraindication for personal or family history of medullary thyroid carcinoma or MEN2 remains on the label. After: The US Adlyxin label lists severe hypersensitivity as its only contraindication.

Peptides: Lixisenatide

Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) · Saved copy

Corrected Oct 6, 2026: MTC and MEN 2 history now reads as a GLP-1 class caution kept by this site, not an Adlyxin contraindication, per the FDA label.

Before: Personal or family history of medullary thyroid carcinoma (precautionary: no boxed warning); Multiple Endocrine Neoplasia syndrome type 2 (MEN2) After: Personal or family history of medullary thyroid carcinoma (MTC) or MEN2: GLP-1 class caution kept by this site; not on the US Adlyxin label

Peptides: Lixisenatide

Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) · Saved copy

Corrected Oct 6, 2026: the MTC and MEN 2 contraindication is on Bydureon and Bydureon BCise, not Byetta, per the Byetta and Bydureon BCise labels.

Before: Personal or family history of medullary thyroid carcinoma (MTC): black box warning After: Personal or family history of medullary thyroid carcinoma (MTC): Bydureon and Bydureon BCise only (boxed warning); not a Byetta contraindication

Peptides: Exenatide (Byetta / Bydureon)

Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) · Saved copy

Corrected Oct 6, 2026: the boxed thyroid C-cell tumor warning is on Bydureon and Bydureon BCise, not Byetta, per the Byetta and Bydureon BCise labels.

Before: Exenatide carries an FDA black box warning for medullary thyroid carcinoma risk. After: Bydureon and Bydureon BCise carry the boxed warning. Byetta carries no boxed warning.

Peptides: Exenatide (Byetta / Bydureon)

Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) · Saved copy

Mounjaro's existing diabetic retinopathy warning (5.7) was revised on Aug 27, 2026, per the FDA label; no new retinopathy warning was added.

Peptides: Tirzepatide

Source: Mounjaro (tirzepatide) prescribing information, SPL version 40, effective 2026-08-27 (openFDA label record) · Saved copy

FDA added a major adverse cardiovascular event risk indication in type 2 diabetes to Mounjaro (S-044, S-045) on Aug 27, 2026, per the updated FDA label.

What this does not mean: SURPASS-CVOT showed noninferiority to dulaglutide, not superiority. Zepbound did not gain this indication.

Peptides: Tirzepatide

Source: Mounjaro (tirzepatide) prescribing information (openFDA label record, SPL version 40, effective Aug 27, 2026) · Saved copy

Zepbound supplement S-041 revised the existing diabetic retinopathy warning (5.8) on Aug 26, 2026, per the updated label; no cardiovascular indication.

Peptides: Tirzepatide

Source: Zepbound (tirzepatide) prescribing information (openFDA label record, SPL version 40, effective Aug 28, 2026) · Saved copy

PCAC backed Semax for the 503A bulks list 8-5-1 on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

Peptides: Semax

Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) · Saved copy

PCAC recommended epitalon for the 503A bulks list on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

Peptides: Epithalon

Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) · Saved copy

PCAC did not back emideltide (DSIP) for the 503A list 6-7-1 on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

What this does not mean: The vote is advice to FDA, not a decision. Emideltide stays off the 503A bulks list unless FDA adds it by notice-and-comment rule.

Peptides: DSIP

Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) · Saved copy

PCAC backed TB-500 for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

Peptides: TB-500

Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) · Saved copy

PCAC backed MOTS-c for the 503A bulks list 7-5-2 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

Peptides: MOTS-c

Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) · Saved copy

PCAC backed KPV for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

Peptides: KPV

Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) · Saved copy

PCAC backed BPC-157 for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

Peptides: BPC-157

Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) · Saved copy

Two Novo Nordisk CagriSema formulation trials (NCT07357740, NCT07357766) were withdrawn before enrolling anyone, posted Jul 9, 2026, per ClinicalTrials.gov.

What this does not mean: Both records say "withdrawn due to strategic reasons" with zero enrolled. It is not a safety or efficacy signal.

Peptides: CagriSema

Source: ClinicalTrials.gov NCT07357766 (and NCT07357740), CagriSema versions compared · Saved copy

FDA extended comments on its 503B proposal for semaglutide, tirzepatide and liraglutide to Jul 30, 2026, per Federal Register 2026-12937.

What this does not mean: An extension of the comment period only. FDA has not made a final decision on the proposal.

Peptides: Semaglutide, Tirzepatide, Liraglutide

Source: Federal Register 2026-12937 (91 FR 38719, Jun 26, 2026) · Saved copy

Lilly posted a pre-approval expanded access program for retatrutide on ClinicalTrials.gov on Jun 5, 2026, per NCT07629401.

What this does not mean: Expanded access is not an FDA approval. It is limited to adults with severe obesity and serious complications who cannot join a trial.

Peptides: Retatrutide

Source: ClinicalTrials.gov NCT07629401, Pre-approval Expanded Access of Retatrutide (LY3437943) · Saved copy

FDA put non-injectable GHK-Cu back in 503A category 1 after a nominator kept that route, per the FDA 503A categories list updated May 14, 2026.

What this does not mean: Category 1 means under evaluation. It is not the 503A bulks list, and injectable GHK-Cu stays out of every category.

Peptides: GHK-Cu

Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) · Saved copy

FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list on May 1, 2026, per Federal Register 2026-08552.

What this does not mean: A proposal, not a final decision. It does not touch the FDA-approved brand products; it concerns bulk substances for outsourcing facilities.

Peptides: Semaglutide, Tirzepatide, Liraglutide

Source: Federal Register 2026-08552 (91 FR 23431, May 1, 2026) · Saved copy

FDA took non-injectable GHK-Cu off 503A category 1 on Apr 22, 2026 after its nominations were withdrawn, per the FDA 503A categories list.

What this does not mean: It concerns 503A compounding nominations only. It is not a new FDA safety finding about GHK-Cu.

Peptides: GHK-Cu

Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) · Saved copy

Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.

What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).

Peptides: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II

Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) · Saved copy · Archived snapshot

FDA granted original approval to Foundayo (orforglipron, NDA 220934) on Apr 1, 2026, per Drugs@FDA.

What this does not mean: The approval covers the Foundayo product and its labeled uses only.

Peptides: Orforglipron

Source: Drugs@FDA record for Foundayo, NDA 220934 (openFDA) · Saved copy

Zepbound labeling supplement S-042 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per the updated FDA label.

Peptides: Tirzepatide

Source: Zepbound (tirzepatide) prescribing information (openFDA label record, SPL version 40; Recent Major Changes lists the warning as removed 02/2026) · Saved copy

Wegovy labeling supplement S-033 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per Drugs@FDA.

Peptides: Semaglutide

Source: Drugs@FDA record for Wegovy, NDA 215256 (openFDA) · Saved copy

Saxenda labeling supplement S-025 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per the updated FDA label.

Peptides: Liraglutide

Source: Saxenda (liraglutide) prescribing information (openFDA label record, SPL version 22, effective Feb 25, 2026) · Saved copy

FDA asked makers to take the suicidal behavior and ideation warning off Saxenda, Wegovy and Zepbound labels on Jan 13, 2026, per an FDA safety communication.

What this does not mean: FDA found no increased risk of suicidal ideation or behavior in its review. The diabetes-only GLP-1 labels never carried this warning.

Peptides: Liraglutide, Semaglutide, Tirzepatide

Source: FDA Drug Safety Communication, Jan 13, 2026: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications · Saved copy

The Lancet posted an expression of concern on Apr 6, 2013 about the cited tesofensine trial (PMID 18950853), per PubMed (PMID 23561987).

Peptides: Tesofensine

Source: Expression of concern, Lancet 2013 Apr 6, PMID 23561987 (on PMID 18950853) · Saved copy · Archived snapshot